Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · see citing works

Mutational landscape and significance across 12 major cancer types

Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419 · see citing works

Next-generation characterization of the Cancer Cell Line Encyclopedia

Ghandi, M., Huang, F. W., Jané-Valbuena, J., Kryukov, G. V., Lo, C. C., McDonald, E. R., Barretina, J., Gelfand, E. T., Bielski, C. M., Li, H., et al. (2019) · Nature · doi:10.1038/s41586-019-1186-3 · Cited by 3,394 · see citing works

Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis

DeBerardinis, R. J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S., & Thompson, C. B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709747104 · Cited by 2,622 · see citing works

Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy

Koppula, P., Zhuang, L., & Gan, B. (2020) · Protein & Cell · doi:10.1007/s13238-020-00789-5 · Cited by 2,551 · see citing works

Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay

Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261 · see citing works

NRF2 and the Hallmarks of Cancer

Rojo de la Vega, M., Chapman, E., & Zhang, D. D. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.022 · Cited by 1,672 · see citing works

The cellular thermal shift assay for evaluating drug target interactions in cells

Jafari, R., Almqvist, H., Axelsson, H., Ignatushchenko, M., Lundbäck, T., Nordlund, P., & Molina, D. M. (2014) · Nature Protocols · doi:10.1038/nprot.2014.138 · Cited by 1,521 · see citing works

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · see citing works

Targeting mutant p53 for efficient cancer therapy

Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889 · cited 1× · see citing works

SynergyFinder 2.0: visual analytics of multi-drug combination synergies

Ianevski, A., Giri, A. K., & Aittokallio, T. A. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa216 · Cited by 882 · see citing works

Correlating chemical sensitivity and basal gene expression reveals mechanism of action

Rees, M. G., Seashore-Ludlow, B. A., Cheah, J. H., Adams, D., Price, E. V., Gill, S., Javaid, S., Coletti, M. E., Jones, V., Bodycombe, N. E., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1986 · Cited by 874 · see citing works

Mutant p53 as a guardian of the cancer cell

Mantovani, F., Collavin, L., & Sal, G. D. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0246-9 · Cited by 779 · see citing works

The GCN2‐ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation

Ye, J., Kumanova, M., Hart, L. S., Sloane, K. L., Zhang, H., Panis, D. N. D., Bobrovnikova-Marjon, E. V., Diehl, J. A., Ron, D., & Koumenis, C. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.81 · Cited by 709 · see citing works

Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis

Romero, R., Sayin, V. I., Davidson, S. M., Bauer, M. R., Singh, S. X., LeBoeuf, S. E., Karakousi, T. R., Ellis, D. C., Bhutkar, A., Sánchez-Rivera, F. J., et al. (2017) · Nature Medicine · doi:10.1038/nm.4407 · Cited by 652 · see citing works

PRIMA-1 reactivates mutant p53 by covalent binding to the core domain

Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592 · see citing works

Glutamine Sensitivity Analysis Identifies the xCT Antiporter as a Common Triple-Negative Breast Tumor Therapeutic Target

Timmerman, L. A., Holton, T., Yuneva, M., Louie, R. J., Padró, M., Daemen, A., Hu, M., Chan, D. A., Ethier, S. P., van ‘t Veer, L. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.020 · Cited by 573 · see citing works

The landscape of cancer cell line metabolism

Li, H., Ning, S., Ghandi, M., Kryukov, G. V., Gopal, S., Deik, A., Souza, A., Pierce, K. A., Keskula, P., Hernandez, D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0404-8 · Cited by 511 · see citing works

Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor

Krall, A. S., Xu, S., Graeber, T. G., Braas, D., & Christofk, H. R. (2016) · Nature Communications · doi:10.1038/ncomms11457 · Cited by 504 · see citing works

Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Hoelzer, D. T., Bassan, R., Dombret, H., Fielding, A. K., Ribera, J., & Buske, C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw025 · Cited by 465 · see citing works

A dominant-negative effect drives selection of <i>TP53</i> missense mutations in myeloid malignancies

Boettcher, S., Miller, P. G., Sharma, R., McConkey, M., Leventhal, M., Krivtsov, A. V., Giacomelli, A. O., Wong, W., Kim, J., Chao, S., et al. (2019) · Science · doi:10.1126/science.aax3649 · Cited by 441 · see citing works

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406 · see citing works

Inhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation

Liu, D. S., Duong, C. P., Haupt, S., Montgomery, K. G., House, C. M., Azar, W. J., Pearson, H. B., Fisher, O. M., Read, M., Guerra, G. R., et al. (2017) · Nature Communications · doi:10.1038/ncomms14844 · Cited by 321 · see citing works

Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers

Ogiwara, H., Takahashi, K., Sasaki, M., Kuroda, T., Yoshida, H., Watanabe, R., Maruyama, A., Makinoshima, H., Chiwaki, F., Sasaki, H., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.12.009 · Cited by 292 · see citing works

TP53 and gastric carcinoma: A review

Fenoglio‐Preiser, C. M., Wang, J., Stemmermann, G. N., & Noffsinger, A. E. (2003) · Human Mutation · doi:10.1002/humu.10180 · Cited by 252 · see citing works

Asparagine Synthetase Chemotherapy

Richards, N. G. J., & Kilberg, M. S. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142520 · Cited by 244 · see citing works

Mutations and Deletions of the TP53 Gene Predict Nonresponse to Treatment and Poor Outcome in First Relapse of Childhood Acute Lymphoblastic Leukemia

Hof, J., Groeneveld‐Krentz, S., van Schewick, C., Körner, G., Shalapour, S., Rhein, P., Karawajew, L., Ludwig, W., Seeger, K., Henze, G., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.8144 · Cited by 209 · see citing works

Amino Acid Deprivation Induces the Transcription Rate of the Human Asparagine Synthetase Gene through a Timed Program of Expression and Promoter Binding of Nutrient-responsive Basic Region/Leucine Zipper Transcription Factors as Well as Localized Histone Acetylation

Chen, H., Pan, Y., Dudenhausen, E. E., & Kilberg, M. S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409173200 · Cited by 197 · see citing works

Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections

Tornesello, M. L., Buonaguro, L., Tatangelo, F., Botti, G., Izzo, F., & Buonaguro, L. (2013) · Genomics · doi:10.1016/j.ygeno.2013.04.001 · Cited by 196 · see citing works

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells

Mohell, N., Alfredsson, J., Fransson, Å., Uustalu, M., Byström, S., Gullbo, J., Hallberg, A., Bykov, V. J. N., Björklund, U., & Wiman, K. G. (2015) · Cell Death &amp; Disease · doi:10.1038/cddis.2015.143 · Cited by 183 · see citing works

Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database

Bykov, V. J. N. (2002) · Carcinogenesis · doi:10.1093/carcin/23.12.2011 · Cited by 172 · see citing works

APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase

Peng, X., Zhang, M.-Q.-Z., Conserva, F., Hosny, G., Selivanova, G., Bykov, V. J. N., Arnér, E. S. J., & Wiman, K. G. (2013) · Cell Death &amp; Disease · doi:10.1038/cddis.2013.417 · Cited by 170 · see citing works

Modulation of Protein-Interaction States through the Cell Cycle

Dai, L., Zhao, T., Bisteau, X., Sun, W., Prabhu, N., Lim, Y. T., Sobota, R. M., Kaldis, P., & Nordlund, P. (2018) · Cell · doi:10.1016/j.cell.2018.03.065 · Cited by 168 · see citing works

Asparagine Synthetase in Cancer: Beyond Acute Lymphoblastic Leukemia

Chiu, M., Taurino, G., Bianchi, M. G., Kilberg, M. S., & Bussolati, O. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01480 · Cited by 168 · see citing works

PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance

Tessoulin, B., Descamps, G., Moreau, P., Maïga, S., Lodé, L., Godon, C., Marionneau-Lambot, S., Oullier, T., Le Gouill, S., Amiot, M., et al. (2014) · Blood · doi:10.1182/blood-2014-01-548800 · Cited by 166 · see citing works

CETSA screening identifies known and novel thymidylate synthase inhibitors and slow intracellular activation of 5-fluorouracil

Almqvist, H., Axelsson, H., Jafari, R., Chen, D., Mateus, A., Haraldsson, M., Larsson, A., Molina, D. M., Artursson, P., Lundbäck, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms11040 · Cited by 165 · see citing works

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine

Bally, C., Adès, L., Renneville, A., Sebert, M., Eclache, V., Preudhomme, C., Mozziconacci, M.-J., de The, H., Lehmann-Che, J., & Fenaux, P. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.03.012 · Cited by 162 · see citing works

l-Asparaginase resistance in human leukemia—Asparagine synthetase

Haskell, C. M., & Canellos, G. P. (1969) · Biochemical Pharmacology · doi:10.1016/0006-2952(69)90375-x · Cited by 152 · see citing works

Activation of Oxidative Stress Response in Cancer Generates a Druggable Dependency on Exogenous Non-essential Amino Acids

LeBoeuf, S. E., Wu, W. L., Karakousi, T. R., Karadal, B., Jackson, S. R., Davidson, S. M., Wong, K.-K., Koralov, S. B., Sayin, V. I., & Papagiannakopoulos, T. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.012 · Cited by 150 · see citing works

Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells

Aslanian, A. M., Fletcher, B. S., & Kilberg, M. S. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3570321 · Cited by 145 · see citing works

Erratum: APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase

Peng, X., Zhang, M., Conserva, F., Hosny, G., Selivanova, G., Bykov, V. J. N., Arnér, E. S. J., & Wiman, K. G. (2017) · Cell Death and Disease · doi:10.1038/cddis.2016.137 · Cited by 134 · see citing works

Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells

Aslanian, A. M., Fletcher, B. S., & Kilberg, M. S. (2001) · Biochemical Journal · doi:10.1042/bj3570321 · Cited by 131 · see citing works

p53 as a hub in cellular redox regulation and therapeutic target in cancer

Eriksson, S. E., Ceder, S., Bykov, V. J. N., & Wiman, K. G. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz005 · Cited by 123 · see citing works

p53-mediated control of aspartate-asparagine homeostasis dictates LKB1 activity and modulates cell survival

Deng, L., Yao, P., Li, L., Ji, F., Zhao, S., Xu, C., Lan, X., & Jiang, P. (2020) · Nature Communications · doi:10.1038/s41467-020-15573-6 · Cited by 119 · see citing works

Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes

Scian, M. J., Stagliano, K. E., Deb, D., Ellis, M. A., Carchman, E. H., Das, A., Valerie, K. C., Deb, S. P., & Deb, S. (2004) · Oncogene · doi:10.1038/sj.onc.1207553 · Cited by 117 · see citing works

Glutaminase activity determines cytotoxicity of l-asparaginases on most leukemia cell lines

Parmentier, J. H., Maggi, M., Tarasco, E., Scotti, C., Avramis, V. I., & Mittelman, S. D. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.04.008 · Cited by 114 · see citing works

Asparagine synthetase in normal and malignant tissues; correlation with tumor sensitivity to asparaginase

Prager, M. D., & Bachynsky, N. (1968) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(68)90273-7 · Cited by 105 · see citing works

A Genome-Wide View of the <i>In vitro</i> Response to <scp>l</scp>-Asparaginase in Acute Lymphoblastic Leukemia

Fine, B. M., Kaspers, G. J. L., Ho, M., Loonen, A. H., & Boxer, L. M. (2005) · Cancer Research · doi:10.1158/0008-5472.291.65.1 · Cited by 103 · see citing works

NQO2 Is a Reactive Oxygen Species Generating Off-Target for Acetaminophen

Miettinen, T. P., & Björklund, M. (2014) · Molecular Pharmaceutics · doi:10.1021/mp5004866 · Cited by 91 · see citing works

Biochemical characterization of U937 cells resistant to L-asparaginase: the role of asparagine synthetase.

Kiriyama, Y., Kubota, M., Takimoto, T., Kitoh, T., Tanizawa, A., Akiyama, Y., & Mikawa, H. (1989) · PubMed · Cited by 80 · see citing works

TP53Mutations in Hypodiploid Acute Lymphoblastic LeukemiaPreprint

Comeaux, E. Q., & Mullighan, C. G. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026286 · Cited by 77 · see citing works

Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246

Haffo, L., Lu, J., Bykov, V. J. N., Martin, S. S., Ren, X., Coppo, L., Wiman, K. G., & Holmgren, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-31048-7 · Cited by 73 · cited 2× · see citing works

Asparaginase pharmacology: challenges still to be faced

Lanvers‐Kaminsky, C. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3236-y · Cited by 61 · see citing works

Ribonucleotide reductase inhibitors suppress SAMHD1 ara‐CTPase activity enhancing cytarabine efficacy

Rudd, S. G., Tsesmetzis, N., Sanjiv, K., Paulin, C. B. J., Sandhow, L., Kutzner, J., Myrberg, I. H., Bunten, S. S., Axelsson, H., Zhang, S. M., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201910419 · Cited by 61 · see citing works

CETSA in integrated proteomics studies of cellular processes

Prabhu, N., Dai, L., & Nordlund, P. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.11.004 · Cited by 60 · see citing works

Asparaginase in the treatment of non-ALL hematologic malignancies

Emadi, A., Zokaee, H., & Sausville, E. A. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2402-3 · Cited by 56 · see citing works

An Inhibitor of Human Asparagine Synthetase Suppresses Proliferation of an L-Asparaginase-Resistant Leukemia Cell Line

Gutierrez, J. A., Pan, Y., Koroniak, Ł., Hiratake, J., Kilberg, M. S., & Richards, N. G. J. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.10.010 · Cited by 55 · see citing works

Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia

Demir, S., Boldrin, E., Sun, Q., Hampp, S., Tausch, E., Eckert, C., Ebinger, M., Handgretinger, R., Kronnie, G. T., Wiesmüller, L., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.199364 · Cited by 55 · see citing works

An efficient proteome-wide strategy for discovery and characterization of cellular nucleotide-protein interactions

Lim, Y. T., Prabhu, N., Dai, L., Go, K. D., Chen, D., Sreekumar, L., Egeblad, L., Eriksson, S., Chen, L., Veerappan, S., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0208273 · Cited by 52 · see citing works

The N-terminal cysteine of human asparagine synthetase is essential for glutamine-dependent activity

Heeke, G. V., & Schuster, S. M. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)47138-x · Cited by 48 · see citing works

SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than <i>TP53</i> Mutation Status

Fujihara, K. M., Corrales Benitez, M., Cabalag, C. S., Zhang, B. Z., Ko, H. S., Liu, D. S., Simpson, K. J., Haupt, Y., Lipton, L., Haupt, S., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0067 · Cited by 48 · see citing works

Monitoring structural modulation of redox-sensitive proteins in cells with MS-CETSA

Sun, W., Dai, L., Yu, H., Puspita, B., Zhao, T., Li, F., Tan, J. L., Lim, Y. T., Chen, M. W., Sobota, R. M., et al. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101168 · Cited by 45 · see citing works

A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death

Ceder, S., Eriksson, S. E., Cheteh, E. H., Dawar, S., Corrales Benitez, M., Bykov, V. J. N., Fujihara, K. M., Grandin, M., Li, X., Ramm, S., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.201910852 · Cited by 41 · see citing works

Methylation of the asparagine synthetase promoter in human leukemic cell lines is associated with a specific methyl binding protein

Ren, Y., Roy, S. S., Ding, Y., Iqbal, J., & Broome, J. D. (2004) · Oncogene · doi:10.1038/sj.onc.1207498 · Cited by 38 · see citing works

PRIMA-1MET induces death in soft-tissue sarcomas cell independent of p53

Grellety, T., Laroche‐Clary, A., Chaire, V., Lagarde, P., Chibon, F., Neuville, A., & Italiano, A. (2015) · BMC Cancer · doi:10.1186/s12885-015-1667-1 · Cited by 32 · see citing works

Epigenetic changes in the repression and induction of asparagine synthetase in human leukemic cell lines

Ding, Y., Li, Z., & Broome, J. D. (2005) · Leukemia · doi:10.1038/sj.leu.2403639 · Cited by 30 · see citing works

Drug synergy scoring using minimal dose response matrices

Mäkelä, P., Zhang, S. M., & Rudd, S. G. (2021) · BMC Research Notes · doi:10.1186/s13104-021-05445-7 · Cited by 25 · see citing works

Nutritional requirements of human leukemic cells

Lazarus, H., McCoy, T. A., Farber, S., et al. (1969) · Experimental Cell Research · doi:10.1016/0014-4827(69)90377-2 · Cited by 21 · see citing works

New use for CETSA: monitoring innate immune receptor stability via post-translational modification by OGT

Drake, W. R., Hou, C., Zachara, N. E., & Grimes, C. L. (2018) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-018-9754-z · Cited by 18 · see citing works

Therapeutic targeting of mutated p53 in acute lymphoblastic leukemia

van Leeuwen, F. N. (2020) · Haematologica · doi:10.3324/haematol.2019.234872 · Cited by 10 · see citing works

SLC7A11 is a superior determinant of APR-246 (Eprenetapopt) response than TP53 mutation statusPreprint

Fujihara, K. M., Corrales-Benitez, M., Cabalag, C. S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.29.398875 · Cited by 3 · see citing works

Drug synergy scoring using minimal dose response matricesPreprint

Mäkelä, P., Zhang, S. M., & Rudd, S. G. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.30.362103 · Cited by 2 · see citing works

Targeting p53 pathways: mechanisms, structures, and advances in therapy

Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016 · see citing works

Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction

Fujihara, K. M., Zhang, B. Z., Jackson, T. D., Ogunkola, M. O., Nijagal, B., Milne, J. V., Sallman, D. A., Ang, C.-S., Nikolic, I., Kearney, C. J., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm9427 · Cited by 103 · see citing works

Asparagine Synthetase Activity of Mouse Leukemias

Horowitz, B., Madras, B. K., Meister, A., Old, L. J., Boyse, E. A., & Stockert, E. (1968) · Science · doi:10.1126/science.160.3827.533 · Cited by 195 · see citing works

Asparaginyl-tRNA and Resistance of Murine Leukaemias to L-Asparaginase

Gallo, R. C., Longmore, J., & Adamson, R. H. (1970) · Nature · doi:10.1038/2271134a0 · Cited by 15 · see citing works

Biochemical characterization of U937 cells resistant to L-asparaginase: the role of asparagine synthetase.

Kiriyama, Y., Kubota, M., Takimoto, T., Kitoh, T., Tanizawa, A., Akiyama, Y., & Mikawa, H. (1989) · PubMed · Cited by 80 · see citing works

Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells

Aslanian, A. M., & Kilberg, M. S. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3580059 · Cited by 72 · see citing works

Asparaginase gene expression is regulated in a complex spatial and temporal pattern in nitrogen‐sink tissues

Grant, M., & Bevan, M. W. (1994) · The Plant Journal · doi:10.1111/j.1365-313x.1994.00695.x · Cited by 33 · see citing works